Skip to main navigation
Skip Navigation
Landos Biopharma
  • - Landos - Corp Menu

  • About Us
    • Our Company
      • Management Team
      • Board of Directors
      • Clinical Advisory Board
    • Contact Us
  • Product Candidates
    • NX-13
    • Preclinical Candidates
    • Clinical Trials
  • Science
    • LANCE Precision Medicine Platform
    • Immunometabolic Pathways
    • Publications
  • Investors/Media
    • Investor/Media Home
    • Press Releases
    • Events & Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investors/Media FAQs
  • Careers
    • Why Landos?
    • Open Positions
Identifying novel pathways at the interface of immunity and metabolism

SEC Filing Details

Document Details

Form
10-Q
Filing Date
May 17, 2021
Document Date
Mar 31, 2021
Form Description
Quarterly report which provides a continuing view of a company's financial position
Filing Group
Quarterly Filings
Company
Landos Biopharma
Issuer
Landos Biopharma, Inc.

Filing Formats

iXBRL
View HTML
Download PDF 618.2 KB
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
XML - XBRL INSTANCE DOCUMENT

Investors/Media

Investor Relations

  • Investor/Media Home
  • Press Releases
  • Events & Presentations
  • Analyst Coverage
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investors/Media FAQs

- Landos - Investor Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
Landos Biopharma, Inc.
PO Box 11239
Blacksburg, VA 24062
info@landosbiopharma.com
(540) 218-2232

- Landos - Footer Menu

  • Site Map
  • Terms of Use
  • Privacy Policy

©2023 Landos Biopharma All Rights Reserved.